thiotepa + carboplatin + topotecan

thiotepa + carboplatin + topotecan is a high-dose combination chemotherapy regimen being investigated by Seattle Children's Hospital for the treatment of children and young adults with recurrent or refractory solid tumors. The regimen combines thiotepa, a polyfunctional alkylating agent that cross-links DNA, with carboplatin, a platinum-based antineoplastic agent, and topotecan, a topoisomerase I inhibitor. This multi-agent approach is designed to overcome drug resistance in aggressive pediatric cancers by inducing synergistic DNA damage. Due to the severe myelosuppression associated with high-dose thiotepa and its combination partners, the protocol is administered with peripheral blood stem cell (PBSC) support (autologous stem cell transplantation) to facilitate hematopoietic recovery. Thiotepa has been a staple in oncology since the 1950s and is frequently used in conditioning regimens for stem cell transplants due to its potent myeloablative properties.

Other names

thiotepa, carboplatin, and topotecan regimenTCT regimenN,N',N''-triethylenethiophosphoramide + carboplatin + topotecan